Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 48, 2008, Pages 19006-19011

  Shan, Jian ^a   Nguyen, Thomas B ^a   Totary Jain, Hana ^a   Dansky, Hayes ^a   Marx, Steven O ^a   Marks, Andrew R ^a  

^a College of Physicians and Surgeons of Columbia University ^*  (United States)

Author keywords

Metabolic syndrome; Neointimal formation; Vascular disease; Vascular smooth muscle cells

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FEMORAL ARTERY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; FEMALE; HUMANS; HYPERPLASIA; LEPTIN; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN KINASES; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION; SIROLIMUS; STENTS; TUNICA INTIMA;

MAMMALIA; MURINAE;

EID: 57749120471     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0809743105     Document Type: Article

References (47)

1. Indolfi C, Mongiardo A, Curcio A, Torella D (2003) Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med 13:142-148.
2. Marks AR (2003) Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 349:1307-1309.
3. Moses JW, et al. (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323.
4. Moussa I, et al. (2004) Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109:2273-2278.
5. Scheen AJ, Warzee F, Legrand VM (2004) Drug-eluting stents: Meta-analysis in diabetic patients Eur Heart J 25:2167-2168; author reply 2168-2169.
6. Sierra-Johnson J, et al. (2007) Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol 100:234-239.
7. Wallace AM, et al. (2001) Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104:3052-3056.
8. Wolk R, et al. (2004) Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 44:1819-1824.
9. Soderberg S, et al. (1999) Leptin is associated with increased risk of myocardial infarction. J Intern Med 246:409-418.
10. Beltowski J (2006) Leptin and atherosclerosis. Atherosclerosis 189:47-60.
11. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763-770.
12. Bell CG, Walley AJ, Froguel P (2005) The genetics of human obesity. Nat Rev Genet 6:221-234.
13. Considine RV, et al. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295.
14. Minocci A, et al. (2000) Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat Metab Disorders 24:1139-1144.
15. Schafer K, et al. (2004) Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 24:112-117.
16. Bodary PF, et al. (2007) Leptin regulates neointima formation after arterial injury through mechanisms independent of blood pressure and the leptin receptor/STAT3 signaling pathways involved in energy balance. Arterioscler Thromb Vasc Biol 27:70-76.
17. Stephenson K, et al. (2003) Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice. Arterioscler Thromb Vasc Biol 23:2027-2033.
18. Nishio K, et al. (2006) Insulin resistance in nondiabetic patients with acute myocardial infarction. Cardiovasc Revasc Med 7:54-60.
19. Piatti P, et al. (2003) Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108:2074-2081.
20. Fruhbeck G (2006) Intracellular signalling pathways activated by leptin. Biochem J 393:7-20.
21. Oda A, Taniguchi T, Yokoyama M (2001) Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 47:141-150.
22. Zahradka P, et al. (2004) Activation of MMP-2 in response to vascular injury is mediated by phosphatidylinositol 3-kinase-dependent expression of MT1-MMP. Am J Physiol 287:H2861-H2870.
23. Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501.
24. Sun SY, et al. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65:7052-7058.
25. Fan QW, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9:341-349.
26. Li L, Mamputu JC, Wiernsperger N, Renier G (2005) Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: Inhibitory effect of metformin. Diabetes 54:2227-2234.
27. Cota D, et al. (2006) Hypothalamic mTOR signaling regulates food intake. Science 312:927-930.
28. Favata MF, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632.
29. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248.
30. Calabro P, Samudio I, Willerson JT, Yeh ET (2004) Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110:3335-3340.
31. Huang J, Kontos CD (2002) Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vasc Biol 22:745-751.
32. Roque M, et al. (2000) Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol 20:335-342.
33. Skalli O, et al. (1986) A monoclonal antibody against alpha-smooth muscle actin: A new probe for smooth muscle differentiation. J Cell Biol 103:2787-2796.
34. Sun J, et al. (2001) Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation 103:2967-2972.
35. Legrand V (2007) Therapy insight: Diabetes and drug-eluting stents. Nat Clin Pract Cardiovasc Med 4:143-150.
36. Hennige AM, et al. (2006) Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J 20:1206-1208.
37. Yang R, Barouch LA (2007) Leptin signaling and obesity: Cardiovascular consequences. Circ Res 101:545-559.
38. Liu B, et al. (2004) The role of phospholipase C and phosphatidylinositol 3-kinase in vascular smooth muscle cell migration and proliferation. J Surg Res 120:256-265.
39. Huang J, et al. (2005) Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia. Arterioscler Thromb Vasc Biol 25:354-358.
40. She QB, et al. (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8:287-297.
41. Vogt PK, Kang S (2006) Kinase inhibitors: Vice becomes virtue. Cancer Cell 9:327-328.
42. Byfield MP, Murray JT, Backer JM (2005) hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 280:33076-33082.
43. Nobukuni T, et al. (2005) Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102:14238-14243.
44. Phung TL, et al. (2007) Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res 67:5070-5075.
45. Gallo R, et al. (1999) Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99:2164-2170.
46. Roque M, et al. (2001) Effect of p27 deficiency and rapamycin on intimal hyperplasia: In vivo and in vitro studies using a p27 knockout mouse model. Lab Invest 81:895-903.
47. Poon M, et al. (1996) Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98:2277-2283.